Cancer Medicine · 2019 · 79 citations · 23 references
MedicineOncologyOncology NursingCancer ControlCancer EpidemiologyOutcomes ResearchCancer DisparitiesCancer Health DisparitiesCancer Survival AnalysisLung CancerCancer Mortality RatesCurative InterventionCurative TherapyEarly DiagnosisNon-small Cell Lung Cancer TreatmentPragmatic Trial DesignPrimary Outcome AnalysisRacial Cancer Disparities
BACKGROUND: Advances in early diagnosis and curative treatment have reduced high mortality rates associated with non-small cell lung cancer. However, racial disparity in survival persists partly because Black patients receive less curative treatment than White patients. METHODS: We performed a 5-year pragmatic, trial at five cancer centers using a system-based intervention. Patients diagnosed with early stage lung cancer, aged 18-85 were eligible. Intervention components included: (1) a real-time warning system derived from electronic health records, (2) race-specific feedback to clinical teams on treatment completion rates, and (3) a nurse navigator. Consented patients were compared to retrospective and concurrent controls. The primary outcome was receipt of curative treatment. RESULTS: There were 2841 early stage lung cancer patients (16% Black) in the retrospective group and 360 (32% Black) in the intervention group. For the retrospective baseline, crude treatment rates were 78% for White patients vs 69% for Black patients (P < 0.001); difference by race was confirmed by a model adjusted for age, treatment site, cancer stage, gender, comorbid illness, and income-odds ratio (OR) 0.66 for Black patients (95% CI 0.51-0.85, P = 0.001). Within the intervention cohort, the crude rate was 96.5% for Black vs 95% for White patients (P = 0.56). Odds ratio for the adjusted analysis was 2.1 (95% CI 0.41-10.4, P = 0.39) for Black vs White patients. Between group analyses confirmed treatment parity for the intervention. CONCLUSION: A system-based intervention tested in five cancer centers reduced racial gaps and improved care for all.
23
The PRECIS-2 tool: designing trials that are fit for purpose
Kirsty Loudon, Shaun Treweek, Frank Sullivan et al. · BMJ · 2015 · 1.8K citations · Full text
Treatment of Stage I and II Non-small Cell Lung Cancer
John A. Howington, Matthew G. Blum, Andrew C. Chang et al. · CHEST Journal · 2013 · 1.4K citations
Racial Differences in the Treatment of Early-Stage Lung Cancer
Peter B. Bach, Laura D. Cramer, Joan L. Warren et al. · New England Journal of Medicine · 1999 · 1K citations · Full text